PRVB News and Press, Provention Bio Inc. From 03/03/21

Provention Bio Announces Publication of Extended Follow-up Data from the Pivotal "At-Risk" TN-10 Study of Teplizumab in Science Translational Medicine -One course of teplizumab delayed insulin dependence by approximately three years and improved beta cell function in at-risk (St...

Provention Bio, Inc. (PRVB) Q4 2020 Earnings Conference Call February 25, 2021 08:00 AM ET Company Participants Robert Doody - Vice President of Investor Relations Ashleigh Palmer - Chief Executive Officer & Co-Founder Jason Hoitt - Chief Commercial Officer Andy Drechsler - Chief Financia...

Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q4 2020 Earnings Call Feb 25, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q4 2020 Earnings Call Transcript

Provention Bio (PRVB): Q4 GAAP EPS of -$0.58 misses by $0.07.Cash, cash equivalents and marketable securities of $121.8MPress Release For further details see: Provention Bio EPS misses by $0.07

Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update -U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diab...

Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations. Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong. Hangzhou Zhongmei Huadong ...

Provention Bio (PRVB) has announced a partnership with a subsidiary of Huadong Medicine to develop and commercialize PRV-3279 in Greater China. The bispecific antibody-based molecule is currently undergoing development against systemic lupus erythematosus (“SLE”).The agreement w...

Provention Bio to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021 - Company also Announces Presentation at the 2021 SVB Leerink Global Healthcare Conference - PR Newswire RED BANK, N.J. , Feb. 18, 2021 /PRNewswire/ -- Prov...

Provention Bio and Huadong Announce Strategic Collaboration to Develop and Commercialize PRV-3279 in Greater China - Provention Bio to receive $6 million upfront payment; up to $11.5 million in research, development and manufacturing funding; and up to $172 million in potential ...

Provention Bio (PRVB) posts positive results from a pre-clinical proof-of-concept study for PRV-3279, a DART (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, conducted in a murine model of gene therapy for Pompe disease.In the study PRV-3279 showed r...